Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03900793 · ClinicalTrials.gov registry record · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
A Phase 1 study of Osteosarcoma, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 4
- Study locations
NCT03900793 is a Phase 1 study of Osteosarcoma that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 41 participants, below the 301-participant average among 46 other Osteosarcoma trials with a reported enrollment target (86% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT03900793, a Phase 1 study of Osteosarcoma, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is a Phase 1/1b clinical trial that aims to determine the Maximally Tolerated Dose of Losartan and Sunitinib Combination Therapy. Patients will first be accrued to the Dose Escalation phase of the study, using a 3+3 design. Medication dosages will increase until a maximally tolerated dose is found. Patients will then be accrued to the Dose Expansion phase of the trial, where efficacy of pre-determined dose will be preliminarily assessed.
Conditions Studied
Interventions
- DRUG Sunitinib
- DRUG Losartan
Study Locations (4)
Colorado
- Children's Hospital Colorado - Aurora
- University of Colorado Hospital - Aurora
California
- Children's Hospital Los Angeles - Los Angeles
Georgia
- Children's Hospital of Atlanta - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2019-08-26 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03900793
The ClinicalTrials.gov registry entry for NCT03900793 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 301-participant average among 46 other Osteosarcoma trials with a reported enrollment target (86% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteosarcoma appearing as the primary indexed condition, and to 2 interventions - of which Sunitinib is the first listed.
NCT03900793 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Colorado, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT03900793 about?
NCT03900793 is a clinical study titled "Losartan + Sunitinib in Treatment of Osteosarcoma". This study is a Phase 1/1b clinical trial that aims to determine the Maximally Tolerated Dose of Losartan and Sunitinib Combination Therapy. Patients will first be accrued to the Dose Escalation phase of the study, using a 3+3 design. Medication dosages will increase until a maximally tolerated dose...
What is the current status of trial NCT03900793?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2019-08-26. Estimated completion is 2027-02.
What conditions does trial NCT03900793 study?
This clinical trial studies the following conditions: Osteosarcoma.
What interventions are being tested in trial NCT03900793?
The interventions under investigation include: Sunitinib (DRUG), Losartan (DRUG).
Who is sponsoring clinical trial NCT03900793?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03900793 being conducted?
This trial has 4 study locations across California, Colorado, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.